Chinook Therapeutics, INC.: insider trades · United States · SEC (Form 4)

About Chinook Therapeutics, INC.

CHINOOK THERAPEUTICS, INC. (ticker KDNY) was a United States biopharmaceutical company focused on kidney disease and historically listed on Nasdaq in the US market (NYSE/NASDAQ context). Headquartered in Seattle, Washington, United States, Chinook was founded in 2019 by a team with deep biotech and venture capital experience, and it was built around a clear thesis: developing precision medicines for rare, severe chronic kidney diseases where treatment options remain limited and unmet medical need is high. Its business profile was that of a clinical-stage company rather than a commercial pharmaceutical group, with enterprise value driven primarily by pipeline progress, clinical data readouts, and regulatory milestones. ([cbinsights.com](https://www.cbinsights.com/company/chinook-therapeutics?utm_source=openai)) The company’s core mission was to discover, develop, and commercialize therapies for nephrology indications such as IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), Alport syndrome, primary hyperoxaluria, and other rare chronic kidney disorders. Chinook’s platform combined single-cell RNA sequencing, human-derived organoids, and translational models to identify differentiated mechanisms of action in kidney disease biology. Key clinical and preclinical programs included atrasentan, BION-1301, and CHK-336, reflecting a pipeline strategy centered on specialized, high-unmet-need indications rather than broad primary care markets. ([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai)) In competitive terms, Chinook aimed to stand out in precision nephrology, a relatively concentrated area where scientific differentiation and strong clinical evidence are critical. Its geographic footprint was largely US-based, with Seattle as its operating center, but it also pursued international expansion through SanReno, a joint venture created to develop, manufacture, and commercialize kidney disease therapies in selected Asian markets. That structure suggested an ambition to build a broader regional presence beyond the domestic US market. ([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai)) The most important recent development was Chinook’s acquisition by Novartis in 2023. SEC filings and exchange notices show that shareholders approved the merger and that the company’s KDNY securities were converted as part of the transaction, after which Chinook ceased to function as an independent listed issuer. For investors, Chinook should therefore be viewed as an acquired biotech asset whose pipeline value was ultimately recognized through a strategic takeout rather than as an ongoing standalone public company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1435049/000119312523164896/d511815ddefa14a.htm?utm_source=openai))